Assessing genetic factors in specific language and learning disorders
Study of the Value of Trio Exome Sequencing in the Etiological Assessment of Specific Non-syndromic Language and Learning Disorders
This study is testing whether looking at the genes of children with severe learning disorders and their parents can help us understand and better manage specific language and learning disorders.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 101 (estimated) |
| Ages | 3 Years to 40 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Trial ID | NCT05939739 on ClinicalTrials.gov |
What this trial studies
This study investigates the role of trio exome sequencing in understanding the genetic basis of specific language and learning disorders (SLLD) in children. It focuses on children aged 3 to 40 who exhibit severe learning disorders and have not previously undergone genetic testing. The study involves collecting blood samples from the affected child and their biological parents to analyze genetic variations that may contribute to these disorders. The findings aim to improve diagnosis and management strategies for SLLD.
Who should consider this trial
Good fit: Ideal candidates are children aged 3 to 40 with severe learning disorders requiring in-school help or intensive rehabilitation.
Not a fit: Patients with confirmed intellectual disabilities or obvious syndromic diagnoses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and targeted interventions for children with specific language and learning disorders.
How similar studies have performed: Other studies have shown promise in using genetic testing to understand learning disorders, suggesting this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Index case suffering from one or more severe learning disorders (requiring in-school help or intensive rehabilitation), justified by neuropsychological and/or speech therapy and/or occupational therapy assessments, reviewed by experts and supplemented if necessary within the framework of the study, and not yet having undergone genetic testing. * Index case aged 3 to 40 years * Sample may be taken from index case and 2 known biological parents * Consent signed by the parents and by the index case if major * Index case and parents covered by national health insurance Exclusion Criteria: * Index case and parents have a condition which, in the opinion of the investigator, would contraindicate the subject's participation in the study. * Intellectual disability confirmed by neuropsychological testing or strongly suspected clinically in the index case and/or his/her parents * Obvious syndromic diagnosis (syndrome or antecedents having definitely led to a developmental disorder) * Persons deprived of liberty by judicial or administrative decision, * Adults under guardianship, * Persons residing in a health or social establishment * Patients in critical situations * Pregnant, parturient or nursing women * Previous array CGH and/or Fragile X testing or any other targeted genetic examination (except standard karyotype).
Where this trial is running
Dijon
- CHU Dijon Bourgogne — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Julian DELANNE
- Email: julian.delanne@chu-dijon.fr
- Phone: 03 80 29 53 13
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.